|
1
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Litvak A and Pietanza MC: Bronchial and
thymic carcinoid tumors. Hematol Oncol Clin North Am. 30:83–102.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chen G, Marx A, Chen WH, Yong J, Puppe B,
Stroebel P and Mueller-Hermelink HK: New WHO histologic
classification predicts prognosis of thymic epithelial tumors.
Cancer. 95:420–429. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang
J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, et al:
Outcome of primary neuroendocrine tumors of the thymus: A joint
analysis of the International thymic malignancy interest group and
the European society of thoracic surgeons databases. J Thorac
Cardiovasc Surg. 149:103–109.e2. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tiffet O, Nicholson AG, Ladas G, Sheppard
MN and Goldstraw P: A clinicopathologic study of 12 neuroendocrine
tumors arising in the thymus. Chest. 124:141–146. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gaur P, Leary C and Yao JC: Thymic
neuroendocrine tumors: A SEER database analysis of 160 patients.
Ann Surg. 251:1117–1121. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Öberg K, Hellman P, Ferolla P and Papotti
M: ESMO Guidelines Working Group. Neuroendocrine bronchial and
thymic tumors: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 23 (suppl 7):vii120–vii123.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jia R, Sulentic P, Xu JM and Grossman AB:
Thymic neuroendocrine neoplasms: Biological behaviour and therapy.
Neuroendocrinology. 105:105–114. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Moran CA and Suster S: Neuroendocrine
carcinomas (carcinoid tumor) of the thymus. A clinicopathologic
analysis of 80 cases. Am J Clin Pathol. 114:100–110.
2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Valli M, Fabris G, Dewar A, Chikte S,
Fisher C, Corrin B and Sheppard MN: Atypical carcinoid tumour of
the thymus: A study of eight cases. Histopathology. 24:371–375.
1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Garcia-Yuste M, Matilla JM, Cueto A,
Paniagua JM, Ramos G, Canizares MA and Muguruza I: Spanish
Multi-centric Study of Neuroendocrine Tumours of the Lung for the
Spanish Society of Pneumonology and Thoracic Surgery
(EMETNE-SEPAR). Typical and atypical carcinoid tumours: Analysis of
the experience of the Spanish multi-centric study of neuroendocrine
tumours of the lung. Eur J Cardiothorac Surg. 31:192–197.
2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mann M, Chowdhury B, Sullivan E, Nicklas
R, Anthracite R and Meyer RJ: Serious asthma exacerbations in
asthmatics treated with high-dose formoterol. Chest. 124:70–74.
2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cardillo G, Rea F, Lucchi M, Paul MA,
Margaritora S, Carleo F, Marulli G, Mussi A, Granone P and Graziano
P: Primary neuroendocrine tumors of the thymus: A multicenter
experience of 35 patients. Ann Thorac Surg. 94:241–246.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
The BT: Thymic carcinoids in multiple
endocrine neoplasia type 1. J Intern Med. 243:501–504.
1998.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Araki T, Sholl LM, Hatabu H and Nishino M:
Radiological features and metastatic patterns of thymic
neuroendocrine tumours. Clin Radiol. 73:479–484. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sanli Y, Garg I, Kandathil A, Kendi T,
Zanetti MJB, Kuyumcu S and Subramaniam RM: Neuroendocrine tumor
diagnosis and management: (68)Ga-DOTATATE PET/CT. AJR Am J
Roentgenol. 211:267–277. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Binderup T, Knigge U, Loft A, Federspiel B
and Kjaer A: 18F-fluorodeoxyglucose positron emission tomography
predicts survival of patients with neuroendocrine tumors. Clin
Cancer Res. 16:978–985. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhu S, Wang ZT, Liu WZ, Zong SX and Li BS:
Invasive atypical thymic carcinoid: Three case reports and
literature review. Onco Targets Ther. 9:6171–6176. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dinter H, Bohnenberger H, Beck J,
Bornemann-Kolatzki K, Schütz E, Küffer S, Klein L, Franks TJ, Roden
A, Emmert A, et al: Molecular classification of neuroendocrine
tumors of the thymus. J Thorac Oncol. 14:1472–1483. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hann CL and Forde PM: Lung and thymic
carcinoids. Endocrinol Metab Clin North Am. 47:699–709.
2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ferolla P, Brizzi MP, Meyer T, Mansoor W,
Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W,
et al: Efficacy and safety of long-acting pasireotide or everolimus
alone or in combination in patients with advanced carcinoids of the
lung and thymus (LUNA): An open-label, multicentre, randomised,
phase 2 trial. Lancet Oncol. 18:1652–1664. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Han B, Sun JM, Ahn JS, Park K and Ahn MJ:
Clinical outcomes of atypical carcinoid tumors of the lung and
thymus: 7-year experience of a rare malignancy at single institute.
Med Oncol. 30(479)2013.PubMed/NCBI View Article : Google Scholar
|
